Skip to content

Abstract B011: HMGA2 controls fibroblast skewing and immune infiltration in basal pancreatic cancer

Sep 2026 · Cancer Research · Vol 86, pp. B011-B011 · 0 citations

TL;DR

The role of tumoral HMGA2 expression in controlling an immunosuppressive TME is demonstrated, a potential biomarker to determine TME phenotype in PDAC patients is highlighted and a novel subtype-specific immunomodulatory therapy is introduced.

Abstract

The basal-like subtype of pancreatic ductal adenocarcinoma (PDAC) is associated with poor outcomes and increased chemoresistance. Expression of high mobility group AT-hook 2 (HMGA2), a chromatin architectural protein, marks basal PDAC cells. Recent efforts to understand the tumor microenvironment (TME) of PDAC have extensively characterized both immune and stromal compartments. In previous work, we have shown that HMGA2+ basal-like pancreatic tumors are associated with higher fibroblastic activation and lower CD8+ T cell infiltrate than HMGA2- classical tumors. To mechanistically determine how HMGA2 expression alters the TME, we implemented three independent data sets; single-cell, microdissected and bulk RNA sequencing and found that HMGA2+ cancer cells also had high expression of ILA. Expression of HMGA2 by tumor cells leads to upregulation of the immunosuppressive markers interleukin 6 (IL6) and leucine-rich repeat containing protein 15 (LRRC15) in associated fibroblasts. Mechanistically, HMGA2 in the tumor cell binds the interleukin 1 alpha (IL1α) promoter, displaces histone linker H1 and upregulates transcription, increasing IL1α in the TME. In vivo, a genetically engineered mouse model with high levels of tumoral HMGA2 also displayed high IL6+ LRRC15+ fibroblast content and low CD8+ T cell content in tumors compared to HMGA2low littermates. We then orthotopically implanted murine KrasLSL-G12D/+, Trp53L/+, Pdx1-Cre, Rosa26YFP/YFP (KPCY) engineered to overexpress HMGA2 (oeHMGA2) or empty vector. oeHMGA2 accelerated disease course, increased metastases, and was sufficient to remodel the TME, including lower CD8+ T cell, and higher NK cell, and Treg populations. These TME changes were all prevented when oeHMGA2 cells were implanted into IL1R1 knock-out mice. Finally, we find that preclinical interruption of the IL1R pathway was sufficient to reverse IL6 and LRRC15 skewing in basal conditioned media-treated human PSCs and naïve murine fibroblasts and in vivo. Blockade of the IL1α signaling axis disrupts this tumor-driven microenvironment phenotype and combines with inhibitors of oncogenic KRAS to improve tumor control. These data demonstrate the role of tumoral HMGA2 expression in controlling an immunosuppressive TME, highlight a potential biomarker to determine TME phenotype in PDAC patients and introduce a novel subtype-specific immunomodulatory therapy. Naomi Yamamoto, Stephanie Dobersch, Tess M. Robertson, Jae Hyung Sim, Adrianne Wallace-Povirk, Nayvin W. Chew, Alex E. Orellana, Joana Aggrey-Fynn, Liberalis Debraj . Boila, Aidan Schutter, Ian M. Loveless, Gun Ho Jang, Shayan Avanessian, Gregory L. Beatty, Sunil R. Hingorani, Camilla Rydberg Millrud, Nina G. Steele, Debora Barbosa Vendramini-Costa, Ralph Francescone, Howard C. Crawford, Faiyaz Notta, Kevin C. Barry, Sita Kugel. HMGA2 controls fibroblast skewing and immune infiltration in basal pancreatic cancer [abstract]. In: Proceedings of the AACR Conference on Pancreatic Cancer: New Frontiers in Biology and Therapeutic Development; 2026 Sep 25-28; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(18_Suppl_2):Abstract nr B011.

View source

Similar papers

Sep 2026

Abstract A002: Transcriptional regulation and membrane sequestration of myeloid-derived TNF in pancreatic cancer

Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy defined by stromal desmoplasia, inflammation, and an immunosuppressive tumor microenvironment (TME) enriched for innate immune cells and characterized by effector T-cell dysfunction. Beyond malignant epithelial cells, the PDAC TME is composed predominantl...

Andrew Adams, H. Amirian, C. Rafie et al. · 0 citations
Sep 2026

Abstract A059: MYC biomolecular condensates contribute to PDAC classical-to-basal transition and immune evasion

MYC is one of the most ubiquitous amplified oncogenes in human cancers. Roughly 30% of pancreatic adenocarcinoma (PDAC) samples show MYC amplification, which is associated with increased aggressiveness and drug resistance. Our recent single cell analysis of 62 primary PDAC showed that MYC amplification promotes class...

Qing Su, Andre Qin, Mark Zarate et al. · 0 citations
Open access Aug 2026

Targeting addiction to HMGB2-driven transcriptional programs in pancreatic cancer.

A small molecule inhibitor is repurposed to interfere with its binding to DNA, restrict chromatin accessibility at promoters, and constrain tumor growth both in vitro and in vivo to show how increased HMGB2 availability represents a transcriptional addiction that fuels cell-cycle progression and growth.

Adi Danieli-Mackay, Ioanna Papadionysiou, Markos Tsitsianopoulos et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.